---
title: "KaroLiver cohort: population-based dataset of curative liver-directed treatment for colorectal liv"
id: "medrxiv-9-cohort-profile-karoliver-a-population-based-cohort-of-patients-receiving"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-9-cohort-profile-karoliver-a-population-based-cohort-of-patients-receiving"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.24.26361235v1?rss=1"
published_at: "2026-08-27T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# KaroLiver cohort: population-based dataset of curative liver-directed treatment for colorectal liv
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-9-cohort-profile-karoliver-a-population-based-cohort-of-patients-receiving
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.24.26361235v1?rss=1)
- **Published At:** 2026-08-27T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The **KaroLiver** cohort is a retrospective, population-based observational cohort of patients treated with curative-intent, liver-directed therapies for **colorectal liver metastases (CRLM)** at Karolinska University Hospital, Stockholm. - The cohort includes all consecutive patients who underwent liver-directed curative treatment for CRLM at the centre; the hospital serves a catchment of about 2.5 million people in the Stockholm–Gotland region. - Patient accrual covers procedures performed from February 2012 through January 2022, currently comprising **811 patients** who underwent **1,204 liver interventions**. - The dataset links whole-slide digital histopathology images with detailed oncological, surgical, radiological, molecular, recurrence and survival data to support analyses of treatment trajectories, outcomes and metastatic tumour biology. - Reported outcomes in the current cohort: median overall survival (OS) 51.0 months (95% CI 46.2–57.1), median recurrence-free survival (RFS) 10.4 months (95% CI 9.2–11.9), and five-year OS 44.9% (95% CI 41.2–48.8%). - Early analyses with KaroLiver identified a liver injury–derived stromal capsule in a subset of metastases associated with improved survival, and have demonstrated histopathological markers of tumour biology, sex-based differences in treatment and survival, and links between post-hepatectomy liver failure and oncological outcomes. - Ongoing and planned research priorities include histology-based prognostic scoring, sex differences in recurrence and retreatment, tumour biology in early-onset versus average-onset CRLM, and CT/MRI radiomics integrated with histopathology. - The cohort is continuously updated under amended ethical approvals; data sharing is supported for approved collaborations with appropriate ethical and regulatory clearances and data agreements. - Ethical approvals were provided by the Swedish Ethical Review Authority (multiple Dnr numbers reported). The authors declared no competing interests. De-identified data are available on reasonable request subject to approvals.
## Clinical Analysis & Structured Key Points
Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre | medRxiv Skip to main content Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre View ORCID Profile Marco Gerling , View ORCID Profile Carlos Fernández Moro , View ORCID Profile Celina Limbecker , View ORCID Profile Annika Viljamaa , View ORCID Profile Sara Harrizi , Yousra Hamidi , Ann-Kathrin Hailer , View ORCID Profile Johanna Sterner , View ORCID Profile Ernesto Sparrelid , Lorand Bozóky , Evelina Tidholm Qvist , View ORCID Profile Ruth Baumgartner , Media Salmonson Schaad , Béla Bozóky , View ORCID Profile Natalie Geyer , View ORCID Profile Jennie Engstrand doi: https://doi.org/10.64898/2026.08.24.26361235 Marco Gerling Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Marco Gerling Carlos Fernández Moro Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Carlos Fernández Moro Celina Limbecker Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Celina Limbecker Annika Viljamaa Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Annika Viljamaa Sara Harrizi Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sara Harrizi Yousra Hamidi Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ann-Kathrin Hailer Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site Johanna Sterner Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Johanna Sterner Ernesto Sparrelid Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ernesto Sparrelid Lorand Bozóky Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site Evelina Tidholm Qvist Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ruth Baumgartner Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ruth Baumgartner Media Salmonson Schaad Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site Béla Bozóky Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site Natalie Geyer Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Natalie Geyer Jennie Engstrand Karolinska Institutet Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jennie Engstrand For correspondence: jennie.engstrand{at}ki.se Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Purpose The Karolinska Liver Metastases (KaroLiver) cohort was established to investigate associations between clinical characteristics and histopathological features in patients treated with curative intent for colorectal cancer liver metastases (CRLM). The cohort combines whole-slide digital histopathology images with detailed oncological, surgical, radiological and survival data, enabling comprehensive analyses of treatment trajectories, clinical outcomes and metastatic tumour biology. Participants KaroLiver is a retrospective observational cohort comprising all consecutive patients who received curative-intent, liver-directed treatment for CRLM at Karolinska University Hospital in Stockholm, Sweden. The hospital is the primary regional referral centre for HPB surgery, serving the population of approximately 2.5 million people in the Stockholm-Gotland healthcare region. Patient enrolment is continuously updated in accordance with amended ethical approvals and evolving scientific questions. The cohort currently comprises 811 patients who underwent 1204 liver interventions between February 2012 and January 2022. Detailed clinical, oncological, surgical, pathological, molecular, recurrence and survival data are collected. Findings to date Median overall survival (OS) in the current cohort is 51.0 months (95% CI 46.2–57.1 months), and median recurrence-free survival (RFS) is 10.4 months (95% CI 9.2–11.9 months). The five-year OS rate is 44.9% (95% CI 41.2–48.8%). Studies using the cohort have so far identified a liver injury-derived stromal capsule in a subset of metastases, associated with improved survival. The cohort has also enabled the identification of histopathological markers of tumour biology, sex-based differences in treatment and survival, and associations between post-hepatectomy liver failure and oncological outcomes. Future plans Current research priorities include advanced histology-based prognostic scoring, sex differences in recurrence and retreatment, tumour biology and outcomes in early-onset versus average-onset CRLM, as well as CT- and MRI-based radiomics, all integrated within KaroLiver's histopathological framework. Data sharing is supported, given that regulatory requirements are met. Retrospective accrual and outcome updates will continue for current and future studies, subject to the required approvals. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Swedish Ethical Review Authority gave ethical approval for this work (Dnr 2019-01571, with amendments Dnr 2020-00428, Dnr 2021-06863-02, Dnr 2022-06588-02, Dnr 2025-05423-02, Dnr 2026-03619-01). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors. Data sharing may be arranged for approved research collaborations upon mutual ethical approval from all relevant parties, signature of an appropriate data access and/or research collaboration agreement, and, where applicable, regulatory clearance. De-identified datasets will be made available to qualified researchers for approved analyses. Funder Information Declared Swedish Research Council , 2018-02023 , 2024-03026 Swedish Cancer Society , 22 2175 Pj , 23 2856 Pj Center for Innovative Medicine , FoUI-988728 Deutsche Forschungsgemeinschaft , #460567311 Swedish Society for Medical Research , PD21-0114 Radium Hemmets Research Funds, https://ror.org/006hbj696 , 221103 Åke Wibergs Stiftelse, https://ror.org/03htnqd27 , M22-0116 Ruth och Richard Julins Stiftelse , 2021-00070 Bengt Ihre Foundation Karolinska Institutet/Cancer Research KI StatRegen Cancer and Allergy Foundation Jeansson Foundation Kliniska forskare Region Stockholm , FoUI-1033370 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted August 27, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre Marco Gerling , Carlos Fernández Moro , Celina Limbecker , Annika Viljamaa , Sara Harrizi , Yousra Hamidi , Ann-Kathrin Hailer , Johanna Sterner , Ernesto Sparrelid , Lorand Bozóky , Evelina Tidholm Qvist , Ruth Baumgartner , Media Salmonson Schaad , Béla Bozóky , Natalie Geyer , Jennie Engstrand medRxiv 2026.08.24.26361235; doi: https://doi.org/10.64898/2026.08.24.26361235 Share This Article: Copy Citation Tools Cohort profile: KaroLiver, a population-based cohort of patients receiving curative liver-directed treatment for colorectal liver metastases at a Swedish tertiary centre Marco Gerling , Carlos Fernández Moro , Celina Limbecker , Annika Viljamaa , Sara Harrizi , Yousra Hamidi , Ann-Kathrin Hailer , Johanna Sterner , Ernesto Sparrelid , Lorand Bozóky , Evelina Tidholm Qvist , Ruth Baumgartner , Media Salmonson Schaad , Béla Bozóky , Natalie Geyer , Jennie Engstrand medRxiv 2026.08.24.26361235; doi: https://doi.org/10.64898/2026.08.24.26361235 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (612) Allergy and Immunology (892) Anesthesia (325) Cardiovascular Medicine (4752) Dentistry and Oral Medicine (473) Dermatology (406) Emergency Medicine (639) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1610) Epidemiology (15796) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6963) Geriatric Medicine (726) Health Economics (1050) Health Informatics (4957) Health Policy (1422) Health Systems and Quality Improvement (1730) Hematology (578) HIV/AIDS (1328) Infectious Diseases (except HIV/AIDS) (16226) Intensive Care and Critical Care Medicine (1157) Medical Education (661) Medical Ethics (150) Nephrology (717) Neurology (7156) Nursing (360) Nutrition (1071) Obstetrics and Gynecology (1225) Occupational and Environmental Health (998) Oncology (3562) Ophthalmology (1032) Orthopedics (392) Otolaryngology (444) Pain Medicine (464) Palliative Medicine (139) Pathology (702) Pediatrics (1770) Pharmacology and Therapeutics (730) Primary Care Research (758) Psychiatry and Clinical Psychology (5810) Public and Global Health (9663) Radiology and Imaging (2371) Rehabilitation Medicine and Physical Therapy (1426) Respiratory Medicine (1236) Rheumatology (631) Sexual and Reproductive Health (762) Sports Medicine (571) Surgery (761) Toxicology (106) Transplantation (301) Urology (285)
## Related Clinical Research

- [Mendelian Randomisation Study Linking the Oral Microbiome to Oral, Oropharyngeal, and Tongue Cance](https://medichelpline.com/clinical-feed/pubmed-42583788.md) (DOI: 10.3290/j.ohpd.c_2778)
- [Trends in Breast, Cervical, and Colorectal Cancer Screening Utilization, 2010–2019 (Commercially I](https://medichelpline.com/clinical-feed/medrxiv-8-trends-in-the-utilization-of-breast-cervical-and-colorectal-cancer-screening.md)
- [Polygenic risk score predicts colorectal cancer across six ancestries and may inform screening](https://medichelpline.com/clinical-feed/medrxiv-12-genetic-prediction-of-colorectal-cancer-risk-in-six-major-ancestries-provides.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)
- [Vitamin D3 dosing in metastatic colorectal cancer: SOLARIS phase 3 trial findings](https://medichelpline.com/clinical-feed/medical-news-today-0-vitamin-d-may-aid-late-stage-colorectal-cancer-treatment-but-which-dosage-is.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.